Overview

Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma

Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
The aim of this trial is to determine the appropriate dose of pixantrone to be used in this combination and obtain data on the combination's safety and activity profile.
Phase:
Phase 1
Details
Lead Sponsor:
CTI BioPharma
Treatments:
Antibodies
BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Fludarabine
Fludarabine phosphate
Pixantrone
Rituximab
Vidarabine